Clovis Oncology Inc. (CLVS) and Its Competitors Financial Results Comparison

Clovis Oncology Inc. (NASDAQ:CLVS) is a company in the Biotechnology industry and that’s how we compare it to its rivals. The contrasting will be based on the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Insider and Institutional Ownership

0% of Clovis Oncology Inc.’s shares are held by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are held by institutional investors. On other hand Clovis Oncology Inc. has 0.5% of its shares held by company insiders and an average of 8.45% insiders ownership for its rivals.


On first table we have Clovis Oncology Inc. and its rivals’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Clovis Oncology Inc. 712,131,147.54% -196.40% -43.00%
Industry Average 812.10% 105.95% 28.39%

Valuation and Earnings

The following data compares Clovis Oncology Inc. and its rivals’ valuation, top-line revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Clovis Oncology Inc. 43.44M 6 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Ratings

Table 3 provides summary of recent ratings for Clovis Oncology Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Clovis Oncology Inc. 1 3 0 2.75
Industry Average 1.10 1.78 2.38 2.81

$5.5 is the average price target of Clovis Oncology Inc., with a potential downside of -55.21%. As a group, Biotechnology companies have a potential upside of 168.19%. Given Clovis Oncology Inc.’s stronger average rating and higher possible upside, research analysts clearly believe Clovis Oncology Inc. is more favorable than its rivals.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Clovis Oncology Inc. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Clovis Oncology Inc. -4.7% -31.27% -40.43% -57.11% -75.79% -41.26%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year Clovis Oncology Inc. had bearish trend while Clovis Oncology Inc.’s competitors had bullish trend.


Clovis Oncology Inc. has a Current Ratio of 4.4 and a Quick Ratio of 4.2. Competitively, Clovis Oncology Inc.’s rivals Current Ratio is 7.07 and has 6.86 Quick Ratio. Clovis Oncology Inc.’s peers have better ability to pay short and long-term obligations than Clovis Oncology Inc.

Volatility and Risk

A beta of 1.81 shows that Clovis Oncology Inc. is 81.00% more volatile than S&P 500. In other hand, Clovis Oncology Inc.’s rivals have beta of 1.77 which is 76.75% more volatile than S&P 500.


Clovis Oncology Inc. does not pay a dividend.


On 4 of the 4 factors Clovis Oncology Inc.’s peers beat Clovis Oncology Inc.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.